Duty to have regard to the life sciences sector and access to new medicines and treatments

Part of Health Service Medical Supplies (Costs) Bill (Programme) (No. 2) – in the House of Commons at 4:45 pm on 15th March 2017.

Alert me about debates like this

Photo of Daniel Zeichner Daniel Zeichner Shadow Minister (Transport) 4:45 pm, 15th March 2017

Does my hon. Friend agree that some of the debates in Westminster Hall and the concerns expressed by Members across the House have been prompted by the fact that the resources for new treatments have not become available in the way that was expected because, as the Secretary of State admitted, although the large amount of rebate from the pharmaceutical sector goes to the NHS, it is not being used specifically for new treatments?

Annotations

No annotations